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Abstract: The growing occurrence of bacterial resistance to conventional antibiotics has called
for the development of new classes of antimicrobial agents. Antimicrobial peptides (AMPs) with
broad antimicrobial spectrum derived from frog skin secretions have been demonstrated to be
promising candidates for new antibiotic development. A proven rich source of these compounds are
the skin secretions of the frogs in the Phyllomedusa genus. In this study, two novel phylloseptin
peptides—phylloseptin-PTa and phylloseptin-PHa—were isolated from the skin secretions of
the South American frogs, Phyllomedusa tarsius (P. tarsius) and Phyllomedusa hypochondrialis
(P. hypochondrialis) through parallel transcriptomic and peptidomic studies. Replicates obtained
by chemical synthesis were structurally analysed and shown to adopt an α-helix configuration
in an amphiphilic environment. Both peptides demonstrated antimicrobial activities against
planktonic Gram-positive bacteria strains, including Staphylococcus aureus, Enterococcus faecalis and
methicillin-resistant Staphylococcus aureus , biofilms, as well as cytostatic effects on the non-small
cell lung cancer cell line, NCI-H157, with relatively low haemolysis on horse erythrocytes and low
cytotoxicity on the human microvascular endothelial cell line, HMEC-1. The discovery of phylloseptin
peptides may further inspire the development of new types of antibiotics.
Keywords: phylloseptins; antimicrobial peptides; anti-biofilm; cytostatic
1. Introduction
Decades of research has revealed amphibian skin secretions as great natural sources of bioactive
compounds, such as peptides, steroids, alkaloids and biogenic amines [1]. Among the bioactive
peptides, antimicrobial peptides (AMPs) comprise the group with the most immediate therapeutic
potential owing to their antimicrobial superiority over conventional antibiotics. The AMPs derived
from amphibian skin secretions have remarkable activities against a great range of microorganisms,
falling into the categories of bacteria, fungi, protozoa and even viruses [2,3]. It has been widely
accepted that cationic AMPs initially interact with the anionic phospholipids in the cell membrane
by electrostatic forces, followed by destruction of cell membranes via hydrophobic interactions
through several different mechanisms and ultimately lead to cell death [4,5]. Thus, AMPs with
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these distinctive membrane interactions may represent a powerful weapon in the fight against resistant
pathogenic microorganisms.
The skin secretions of neotropical frogs of the subfamily Phyllomedusinae, which have attracted
research attention worldwide in recent decades, contain an abundant variety of active peptides [6]
making these secretions an excellent source for AMP discovery [7]. This subfamily is further
classified into seven major genera, namely Agalychnis, Cruziohyla, Hylomantis, Pachymedusa, Phasmahyla,
Phrynomedusa, and Phyllomedusa, in which diverse bioactive peptides have been found and grouped
into structurally-related families [8]. The high degree of conservation present in the coding sequence of
the signal peptides in their biosynthetic precursors suggests their homologous phylogenetic ancestry,
while the high degree of variation displayed in the mature peptides reveals their natural molecular
evolutionary strategies in different environments [9–11].
Phylloseptin peptides, representing a class of AMPs discovered from the skin secretions of
Phyllomedusinae subfamily leaf frogs, share several common primary structure features, including
a general length of 19–21 amino acid residues, an highly-conserved N-terminal FLSL{I/L}P
sequence, C-terminal amidation and α-helical configurations in membrane or membrane-mimetic
environments [12]. While the C-terminal amidation is a common post-translational modification found
in many AMPs, the action of the amidation varies, for example, enhancing the helical stability of
the peptides on membrane surface, or increasing the cationicity of peptides, which improves their
antimicrobial activities [13,14].
Due to their potent antimicrobial activities and relatively low haemolytic effects, phylloseptin
peptides are considered to be promising antimicrobial agents [15–17]. They have been reported
to have broad-spectrum antimicrobial activities against bacteria in both planktonic and biofilm
growth modes, fungi and protozoa while possessing low haemolytic activities [16–19]. Additionally,
anticancer activities were revealed in a phylloseptin peptide, phylloseptin-PBa, in a recent study,
where the peptide selectively interacted with pathogens and cancer cells, and showed lower cytotoxicity
against normal mammalian cells [15]. In addition, several phylloseptin peptides have been found
to be effective against the viability of protozoa such as Trypanosoma cruzi (T. cruzi) and Leishmania,
an example of which being phylloseptin-7 and phylloseptin-8, isolated by Pinto and his colleagues
from Phyllomedusa nordestina. These peptides were able to target the plasma membranes of T. cruzi and
lead to cell death, which make them promising anti-parasitic drug candidates [20].
In this study, two phylloseptin peptides—phylloseptin-PTa and phylloseptin-PHa—were
individually discovered from the skin secretions of the Brown-bellied Leaf Frog, Phyllomedusa tarsius
(P. tarsius) and the Orange-legged Leaf Frog, Phyllomedusa hypochondrialis (P. hypochondrialis), via the
employment of ‘shotgun’ cloning of skin secretion-derived cDNAs combined with tandem mass
(MS/MS) spectrometric analysis of skin secretion peptides. Replicates of phylloseptin-PTa and
phylloseptin-PHa were acquired by solid-phase peptide synthesis, and their biological activities
were investigated in various bioassays.
2. Results
2.1. ‘Shotgun’ Cloning of cDNAs Encoding the Phylloseptin-PTa Precursor from the Skin Secretions of
P. tarsius and the Phylloseptin-PHa Precursor from the Skin Secretions of P. hypochondrialis
Through a “shotgun” cloning strategy, the cDNAs encoding biosynthetic precursors of
phylloseptin-PTa and phylloseptin-PHa were consistently and repeatedly cloned from the cDNA
libraries constructed using the skin secretions of P. tarsius and P. hypochondrialis, respectively (Figure 1).
Both prepropeptides consist of 66 amino acid residues organised in five domains: a putative signal
peptide region of 22 amino acid residues, an acidic spacer domain, a typical cleavage site -Lys-Arg-
(-KR-), a mature peptide region of 19 amino acid residues and a C-terminal Gly (G) residue which
acts as an amide donor for post-translational amidation. BLAST search using the National Center for
Biotechnology Information (NCBI) protein Basic Local Alignment Search Tool (BLASTp) showed that
the nucleotide and amino acid sequences of both precursors exhibited high degree of similarity to
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phylloseptin-PT previously identified from P. tarsius (Accession LT591888.1) [21], and phylloseptin-2
from P. hypochondrialis (Accession AM229009.1) [22] (Figure 2). The prepropeptides-encoding cDNAs
sequences of phylloseptin-PTa and phylloseptin-PHa have been deposited in the EMBL Nucleotide
Sequence Database under the accession codes LT703448 and LT860204, respectively.
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Figure 1. Nucleotide and translated open-reading frame amino acid sequence of cloned cDNA 
encoding the precursor of (a) phylloseptin-PTa and (b) phylloseptin-PHa. The putative signal peptide 
is double-underlined, the mature peptide is single-underlined and the termination codon is marked 
by an asterisk. 
Figure 1. Nucleotide and translated open-reading frame amino acid sequence of cloned cDNA
encoding the precursor of (a) phylloseptin-PTa and (b) phylloseptin-PHa. The putative signal peptide
is double-underlined, the mature peptide is single-underlined and the termination codon is marked by
an asterisk.
Molecules 2017, 22, 1428 4 of 21
Molecules 2017, 22, 1428 4 of 20 
 
 
(a) 
 
(b) 
Figure 2. Alignments of (a) nucleotides and (b) translated open-reading frame amino acids sequences 
of biosynthetic precursors of phylloseptin-PTa, phylloseptin-PHa, phylloseptin-2 and phylloseptin-
PT established by the Vector NTI Advance 11.5.1 package. The identical and conservative regions are 
highlighted in yellow and blue, respectively. 
2.2. Isolation and Primary Structural Identification of Phylloseptin-PTa and Phylloseptin-PHa 
The RP-HPLC fractions containing the peptides, of which the molecular mass obtained by 
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) were 
consistent with the computed masses of deduced phylloseptin-PTa and phylloseptin-PHa were 
further analysed by MS/MS spectrometry (Figures 3 and 4). The fragmented b and y ions confirmed 
the primary structures, as well as the post-translational modification of C-terminal amidation of both 
novel phylloseptins (Table 1). 
Figure 2. Alignments of (a) nucleotides and (b) translated open-reading frame amino acids sequences
of biosynthetic precursors of phylloseptin-PTa, phylloseptin-PHa, phylloseptin-2 and phylloseptin-PT
established by the Vector NTI Advance 11.5.1 package. The identical and conservative regions are
highlighted in yellow and blue, respectively.
2.2. Isolation and Primary Structural Identification of Phylloseptin-PTa and Phylloseptin-PHa
The RP-HPLC fractions containing the peptides, of which the molecular mass obtained by
matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) were
consistent with the computed masses of deduced phylloseptin-PTa and phylloseptin-PHa were further
analysed by MS/MS spectrometry (Figures 3 and 4). The fragmented b and y ions confirmed the
primary structures, as well as the post-translational modification of C-terminal amidation of both
novel phylloseptins (Table 1).
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Figure 3. Reversed-phase high performance liquid chromatography (RP-HPLC) chromatograms of the
skin secretions from (a) P. tarsius and (b) P. hypochondrialis with arrows showing the absorbance peaks
corresponding to mature phylloseptin-PTa and phylloseptin-PHa, respectively. The Y-axis shows the
relative absorbance in absorbance units at a wavelength of 214 nm and the X-axis shows the retention
time in minutes.
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Figure 4. Annotated tandem mass (MS/MS) fragmentation spectra of (a) phylloseptin-PTa and
(b) phylloseptin-PHa with observed b ions and y ions labelled in blue and red, respectively.
Table 1. Predicted singly-charged b ions and y ions arising from MS/MS fragmentation of (a)
phylloseptin-PTa and (b) phylloseptin-PHa. Actual fragment ions observed following MS/MS
fragmentation are indicated in blue and red.
#1 b(1+) b(2+) Seq. y(1+) y(2+) #2
(a)
1 148.08 74.54 F 19
2 261. 6 131.08 1785.15 8 . 8 18
3 348.19 174.60 S 1672.06 8 .54 17
4 461.15 231.14 L 1585.03 793.02 16
5 574.18 287.68 I 1471.95 736.48 15
6 671.69 336.21 P 1358.75 679.94 14
7 799.51 400.26 K 1261.81 631.41 13
8 912.59 456.80 I 1133.71 567.36 12
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Table 1. Cont.
#1 b(1+) b(2+) Seq. y(1+) y(2+) #2
(a)
9 983.63 492.32 A 1020.71 510.82 11
10 1040.65 520.83 G 949.59 475.30 10
11 1097.67 549.34 G 892.82 446.79 9
12 1210.71 605.88 I 835.55 418.28 8
13 1281.79 641.40 A 722.47 361.74 7
14 1352.83 676.92 A 651.43 326.22 6
15 1465.82 733.46 L 580.39 290.70 5
16 1536.94 768.98 A 467.31 234.16 4
17 1664.89 833.03 K 396.27 198.64 3
18 1802.11 901.56 H 268.18 134.59 2
19 L-Amidated 131.12 66.06 1
(b)
1 148.08 74.54 F 19
2 261.16 131.08 L 1794.03 897.52 18
3 348.19 174.60 S 1680.94 840.98 17
4 461.28 231.14 L 1593.91 797.46 16
5 574.17 287.68 I 1480.83 740.92 15
6 671.09 336.21 P 1367.68 684.38 14
7 742.45 371.73 A 1270.69 635.85 13
8 813.49 407.25 A 1199.65 600.33 12
9 926.57 463.79 I 1128.80 564.81 11
10 1013.60 507.31 S 1015.53 508.27 10
11 1084.64 542.82 A 928.50 464.75 9
12 1183.71 592.36 V 857.46 429.24 8
13 1270.74 635.87 S 758.37 379.70 7
14 1341.78 671.39 A 671.36 336.18 6
15 1454.64 727.93 L 600.17 300.67 5
16 1525.67 763.45 A 487.31 244.12 4
17 1640.71 820.47 N 416.19 208.61 3
18 1777.00 889.00 H 302.16 151.58 2
19 F-Amidated 165.10 83.05 1
2.3. Verification of Synthetic Phylloseptin-PTa and Phylloseptin-PHa
Phylloseptin-PTa (FLSLIPKIAGGIAALAKHL-NH2) and phylloseptin-PHa (FLSLIPAAISAVS
ALANHF-NH2) were chemically synthesised, purified, and lyophilised prior to being analysed in
bioassays. The authenticity of the purified synthetic phylloseptin-PTa and phylloseptin-PHa was
verified by RP-HPLC and MALDI-TOF MS, as shown in Figures 5 and 6, respectively, indicating the
purity of the purified synthetic peptides no less than 95%.
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2.4. Secondary Structure Determination of Phylloseptin-PTa and Phylloseptin-PHa by Circular Dichroism
The processed spectra in Figure 7 suggest that both purified synthetic phylloseptin-PTa and
phylloseptin-PHa displayed α-helical conformation based on double-negative bands at 208 nm and
222 nm in the 10 mM NH4Ac with 50% TFE, and the calculated α-helicity was 0.34 and 0.27, respectively,
using the K2D analysis programme on the DICHROWEB online server.
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Figure 7. The CD spectra of purified synthetic (a) phylloseptin-PTa and (b) phylloseptin-PHa plotted as
mean residue ellipticity (deg cm2 dmol−1) versus wavelength (nm) suggested α-helical conformation
in the 10 mM NH4Ac with 50% TFE analysed from 240 nm to 200 nm using K2D analysis programme
and processed via DICHROWEB online server.
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2.5. Antimicrobial and Haemolytic Activities of Synthetic Phylloseptin-PTa and Phylloseptin-PHa
Two purified synthetic phylloseptins exhibited different strengths of activities against the growth
of tested microorganism and horse erythrocytes (Table 2). Phylloseptin-PTa demonstrated a more
potent antimicrobial activity than phylloseptin-PHa against all the tested microorganisms and a
significant increase of cytotoxicity on erythrocytes. Both synthetic peptides were more potent against
tested Staphylococcus spp. and C. albicans than E. faecalis and E. coli. Additionally, both peptides were
able to eradicate the biofilm formed by S. aureus (Figure 8) with phylloseptin-PTa being 8-fold more
effective than phylloseptin-PHa. The minimum biofilm eradication concentration (MBEC) of either
phylloseptin-PTa or phylloseptin-PHa against S. aureus biofilm was identical to their respective MIC
recorded for planktonic S. aureus.
Table 2. Antimicrobial activity-minimum inhibitory concentration (MIC) determinations and
haemolytic activity of purified synthetic phylloseptins. The half haemolytic concentration (HC50)
and 10% haemolytic concentration (HC10) were analyse by Graphpad Prism Software (version 6.0).
MIC (µg·mL−1/ µM) Haemolysis
Peptide S. aureusNCTC 10788
MRSA
NCTC 12493
E. faecalis
NCTC 12697
E. coli
NCTC 10418
C. albicans
NCYC 1467
% lysis
at MIC 1
HC10
(µM)
HC50
(µM)
Phylloseptin-PTa 8/4.14 8/4.14 32/16.56 32/16.56 4/2.07 4.42% 7.79 22.8
Phylloseptin-PHa 64/32.97 64/32.97 512/263.78 >512/>263.78 256/131.89 2.52% 76.5 109.5
1 MIC observed against S. aureus.
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Figure 8. Minimum biofilm eradication concentrations (MBECs) of purified synthetic phylloseptin-PTa
and phylloseptin-PHa against biofilm formed by S. aureus. Data represent means ± standard error of
mean (SEM) of three independent experiments with five replicates.
2.6. Scanning Electron Microscopy Observation of S. aureus Biofilms and Peptide Treated S. aureus Biofilms
In order to gain a more informative insight into the interaction of purified synthetic
phylloseptin-PTa and phylloseptin-PHa with S. aureus biofilms, scanning electron microscopy was
employed to observe the untreated S. aureus biofilms (Figure 9a) as well as those treated by either
of the purified synthetic peptides (Figure 9b–e). The results revealed that both phyllospetins were
capable to eradicate the formed biofilm at the concentrations of their respective MBEC and 2 ×MBEC.
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phylloseptin-PTa and phylloseptin-PHa. (a) Images of S. aureus biofilms only; (b) Images of S. aureus 
biofilms treated with phylloseptin-PTa at MBEC; (c) Images of S. aureus biofilms treated with 
phylloseptin-PTa at 2 × MBEC; (d) Images of S. aureus biofilms treated with phylloseptin-PHa at 
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2.7. Cytostatic Activities of Synthetic Phylloseptin-PTa and Phylloseptin-PHa on Non-Small Cell Lung 
Cancer Cells H157 
Purified synthetic phylloseptin-PTa and phylloseptin-PHa showed cytostatic effects against the 
proliferation of H157 cells (Figure 10a,b) with the half inhibitory concentration (IC50) values of 6.73 μM 
and 14.10 μM, respectively, calculated by the GraphPad Prism Software (version 6.0). In the meantime, 
although phylloseptin-PHa exhibited mild cytotoxicity against human microvessel endothelial cells, 
HMEC-1, phylloseptin-PTa showed considerably cytotoxicity at 100 μM (Figure 10c,d). 
Figure 9. Scanning electron microscopy images of S. aureus biofilms treated with purified synthetic
phylloseptin-PTa and phylloseptin-PHa. (a) Images of S. aureus biofilms only; (b) Images of S. aureus
biofilms treated with phylloseptin-PTa at MBEC; (c) Images of S. aureus biofilms treated with
phylloseptin-PTa at 2 × MBEC; (d) Images of S. aureus biofilms treated with phylloseptin-PHa at
MBEC; (e) Images of S. aureus biofilms treated with phylloseptin-PHa at 2 ×MBEC. Scale bars were set
at 20 µm and 10 µm.
2.7. Cytostatic Activities of Synthetic Phylloseptin-PTa and Phylloseptin-PHa on Non-Small Cell Lung Cancer
Cells H157
Purified synthetic phylloseptin-PTa and phylloseptin-PHa showed cytostatic effects against the
proliferation of H157 cells (Figure 10a,b) with the half inhibitory concentration (IC50) values of 6.73 µM
and 14.10 µM, respectively, calculated by the GraphPad Prism Software (version 6.0). In the meantime,
although phylloseptin-PHa exhibited mil cytotoxicity against human microvessel endothelial cells,
HMEC-1, phylloseptin-PTa showed considerably cytotoxicity at 100 µM (Figure 10c,d).
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Figure 10. Anti-proliferative effects of purified synthetic (a) phylloseptin-PTa and (b) phylloseptin-PHa
on non-small cell lung cancer cells H157, and purified synthetic (c) phylloseptin-PTa and
(d) phylloseptin-PHa on human microvessel endothelial cells HMEC-1 after 24 h incubation.
Data represent means ± SEM of three independent experiments with five replicates. M represents
cells in medium, V represents cells in 1% DMSO medium as the vehicle control. **** p < 0.0001,
* p < 0.05 by one-way analysis of variance followed by Dunnett’s multiple comparisons tests with
vehicle control group.
2.8. Therapeutic Index of Phylloseptin-PTa and Phylloseptin-PHa
The therapeutic indexes (TIs) of phylloseptin-PTa and phylloseptin-PHa in treating Gram-positive
bacteria were calculated by comparing HC10 to the geometric mean (GM) of MICs of the assessed
Gram-positive bacteria [23]. The TI for eradicating S. aureus forming biofilm was calculated by
comparing HC10 to MBEC [24]. As shown in Table 3, neither phylloseptin-PTa nor phylloseptin-PHa
caused haemolysis at their MICs and MBECs.
Table 3. TIs of phylloseptin-PTa and phylloseptin-PHa as Gram-positive bacteriostatic agents and S.
aureus biofilm eradicating agents
TI on Gram-Positive Bacteria TI on S. aureus Biofilm
Peptide HC10 HC10
/GM /MBEC
Phylloseptin-PTa 1.19 1.88
Phylloseptin-PHa 1.66 3.32
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3. Discussion
The increase in antibiotic resistance incidents worldwide poses a severe threat to the fight against
infectious diseases, urging the development of alternative antimicrobial drugs with low resistance
induction potential. In this study, two novel phylloseptin peptides were discovered and showed
promising antimicrobial activities against the tested planktonic microorganisms with a higher potency
against the Gram-positive bacteria including the methicillin-resistant bacteria MRSA. The difference
in the antimicrobial activities of phylloseptins on different microorganisms may be a result of the
different structure in the target cell membranes. Sheltered under an additional outer membrane
with abundant acidic lipopolysaccharides exterior to the inner anionic phospholipid membrane,
Gram-negative bacteria are usually more resistant to antibiotics than Gram-positive bacteria, due to
their more complex cellular structure.
The classical models of membrane disruption of antimicrobial peptides include the toroidal pore
model, carpet model and barrel-stave model, in which peptide-lipid alternating channels, micellar
structures and peptide channels, are formed, respectively [5]. Since the MICs of phylloseptin-PTa
were relatively low, the mechanism of phylloseptin-PTa was not estimated to be via the carpet model,
which is most likely to occur at high peptide concentrations in vitro [5]. Besides, it was reported
that the barrel-stave model had only been evidenced for a small number of peptides due to the
stringent criteria for forming transmembrane pores. For example, hydrophobic and charged residues
should be spaced accurately, and the peptide should be long enough to cross the membrane [25].
Hence, it is speculated that phylloseptin-PTa might act via the toroidal pore model for microbial
membrane disruption, which is a well-characterised model deduced mainly from peptides having
α-helical secondary structures, such as the magainins, as both phylloseptin-PTa and phylloseptin-PHa
formed α-helical secondary structure in a membrane mimic environment. In the toroidal pore model,
peptides adopt α-helical structures as they interact with bacterial membranes [4], and by hydrophobic
interaction, the hydrophobic areas of peptides interact with the polar head groups of membranes
and induce membrane curvature, promoting the bending of the lipid monolayers [4,26]. Similarly,
phylloseptin-PHa was also predicted to induce the toroidal pore model to disrupt membrane due to
the structural characteristics of phylloseptins. However, the MICs were not as low due to a deficiency
of electrostatic interaction, which may decrease the efficiency of the initiating attachment, as well as
the large α-helix domain of phylloseptin-PTa than phylloseptin-PHa.
The next interesting character of phylloseptin-PTa and phylloseptin-PHa is their ability to inhibit
bacteria biofilms. Biofilms are communities of bacteria embedded in a self-produced matrix, consisting
of extracellular polymeric substances including polysaccharides, proteins and DNA. Because the
biofilm-forming bacteria are more resistant to current antibiotics and host immune responses, bacterial
biofilms often cause chronic and recurrent infections [27,28]. In this light, new treatment methods for
biofilm-related infections are required. In order to study the anti-biofilm activity of phylloseptin-PTa
and phylloseptin-PHa, an MBEC assay against a S. aureus-formed biofilm was carried out. The MBECs
of either phylloseptin-PTa or phylloseptin-PHa against S. aureus biofilm was identical to their respective
MICs recorded for planktonic S. aureus. Although the anti-biofilm mechanisms of peptides were not
investigated, the identical MIC and MBEC values of each peptide suggest that the mechanisms of
anti-biofilm activity might be similar to that involved in killing planktonic bacteria [27]. However,
because phylloseptin-PTa showed more potent against S. aureus biofilm than phylloseptin-PHa did,
it was suggested that the anti-biofilm activity could be influenced by the physiochemical properties of
the peptides, such as charges, hydrophobicity and α-helicity.
In addition to their antimicrobial activities, phylloseptin-PTa and phylloseptin-PHa were found
to inhibit the proliferation of the non-small lung cancer cell line H157. Previous research has indicated
that cancer cell death is correlated with cytomembrane lysis [29]. Since cancer cell membranes are
negatively charged, the more positively charged phylloseptin-PTa could better move into contact with
the cell surfaces, interact with zwitterionic phospholipids, and lead to more significant membrane
disruption and cell death eventually [30,31]. However, both phylloseptin-PTa and phylloseptin-PHa
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were not able to inhibit the prostate and breast cancer cells, which is likely caused by the high ratio of
cholesterol possession of these cells that protect the membrane from interaction with and lysis by the
peptides [32].
The superiority of phylloseptin-PTa over the recently discovered phylloseptins include stronger
antimicrobial potency and broader antimicrobial spectrum, as shown in Table 4 [15,16,21]. Furthermore,
the toxicity of phylloseptin-PTa and phylloseptin-PHa was evaluated using normal mammalian cells
and horse red blood cells. Both peptides showed very low toxicity at their effective concentrations
in the inhibition of Gram-positive bacteria, S. aureus-formed biofilms and non-small cell lung cancer
cell line H157, which were collectively reflected by the TI values as shown in Table 3. The selective
activities of phylloseptin-PTa and phylloseptin-PHa on different cells are associated with both the
characteristics of peptides per se and the target cell membranes. The positively charged amino
acid residues of phylloseptin-PTa were suggested to selectively and electrostatically interact with
numerous negatively charged molecules, such as phosphatidylserine (PS) and CL in bacteria, PS and
O-glycosylated mucins in cancer cells, driving phylloseptin-PTa to accumulate around the cell
surfaces [33]. As a consequence, the hydrophobicity of phylloseptin-PTa and phylloseptin-PHa could
then induce membrane permeabilisation and disruption. The ideal ratios of hydrophobicity of both
phylloseptins would produce a lower chance of hydrophobic interaction with the neutral components
such as phosphatidylcholine (PC) and phosphatidylethanolamine (PE), in normal cell membranes [4].
Table 4. The comparisons of phylloseptin-PTa with the recently reported phylloseptins in terms of
characteristics and biological activities.
MIC (µg·mL−1/µM)
Phylloseptin-PTa Phylloseptin-PHa Phylloseptin-Du Phylloseptin-Co Phylloseptin-PBa Phylloseptin-PT
S. aureus 8/4.14 64/32.97 8/3.90 8/4.06 8/3.99 512/264.33
C. albicans 4/2.07 256/131.89 16/7.81 16/8.12 8/3.99 512/264.33
E. coli 32/16.56 >512/>263.78 128/62.45 128/64.93 128/63.84 >512/>264.33
MBEC (µg·mL−1/µM)
S. aureus 8/4.14 64/32.97 16/7.81 16/8.12 nr 3 nr 3
3 Means not reported.
4. Materials and Methods
4.1. Acquisition and Collection of Skin Secretions of P. tarsius and P. hypochondralis
Specimens of adult P. tarsius and P. hypochondrialis (n = 3) were commercially purchased from
Mr. Juan Chavez, Venom Peru Company (PeruBiotech E.I.R.L, Huánuco, Peru) and were maintained
in a simulated living environment. These frogs were fed crickets three times per week. After adapting
to new surroundings for more than three months, skin secretions were collected from dorsal skin by
gentle squeezing [34]. Then the skin secretions were rinsed from the skin with deionised water into a
chilled beaker, and snap-frozen in liquid nitrogen and lyophilised. The product was stored at −20 ◦C
prior to analysis. All procedures were vetted and carried out under appropriate UK Animal Research
licenses and were consistent with both local and national animal experimentation ethics.
4.2. ‘Shotgun’ Cloning of Prepropeptide Encoding cDNAs
An aliquot of 5 mg of lyophilised skin secretions were dissolved in 1 mL of lysis/binding buffer
(Life Technologies, Oslo, Norway). Magnetic oligo-dT Dynabeads (Life Technologies) were applied
to isolate mRNAs based on A-T pairing according to the manufacturer’s protocol. Then the isolated
mRNAs were used as templated for the construction of a cDNA library of P. tarsius and P. hypochondrialis
skin secretion. The cDNA library was subsequently subjected to a 3′-RACE PCR procedures using
BD SMART™ RACE cDNA Amplification Kit (Clontech, Palo Alto, CA, USA). The degenerate sense
primer (S1; 5′-ACTTTCYGAWTTRYAAGMCCAAABATG-3′) was designed to the highly-conserved
domain of the 5′-untranslated region of previously-characterised homologous peptide cDNAs from
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several species of the Phyllomedusa genus, and was used in combination with a nested universal primer
(NUP) provided with the kit. The PCR products were purified and cloned using a pGEM-T easy
vector system (Promega Corporation, Southampton, UK) and sequenced using an ABI 3730 automated
sequencer (Applied Biosystems, Foster City, CA, USA). The similarity of the nucleotide and translated
amino acid sequences of the novel peptide precursor with known sequences were analysed using
NCBI protein BLAST tool. The sequence alignments were established by the Vector NTI Advance
11.5.1 package. The nucleotide sequence of the cDNA encoding the novel peptide precursor was
registered with and is permanently available at the European Nucleotide Archive (ENA) browser at
http://www.ebi.ac.uk/ena/data/view/.
4.3. Isolation and Identification of Novel Peptides and their Primary Structural Analysis
An aliquot of 5 mg of lyophilised skin secretions were dissolved in 1 mL of trifluoroacetic acid
(TFA)/water (0.05/99.95, v/v) and clarified by centrifugation (2500× g for 5 min). The supernatant
was then injected and pumped onto a RP-HPLC column (Jupiter, C5, 300 Å, 5 µm, 250 mm × 4.6 mm,
Phenomenex, Macclesfield, Cheshire, UK) which was attached to a RP-HPLC system (Waters, Milford,
MA, USA). The sample was eluted with a linear gradient from TFA/water (0.05/99.95; v/v) to
TFA/water/acetonitrile (0.05/19.95/80.00; v/v/v) in 240 min at a flow rate of 1 mL/min, and all
fractions were collected at one minute intervals. The collected fractions were analysed by a Voyager
DE MALDI-TOF MS (Perseptive Biosystems, Bedford, MA, USA) in a positive detection mode using
α-cyano-4-hydroxycinnamic acid matrix. The fraction containing the peptide with a molecular mass
similar to the putative cDNA-encoding peptide was analysed by tandem mass (MS/MS) fragmentation
using an LCQ-Fleet ion-trap mass spectrometer (ThermoFisher Scientific, San Francisco, CA, USA).
4.4. Solid-phase Peptide Synthesis of Novel Peptides
Phylloseptin-PTa and phylloseptin-PHa were synthesised by Fmoc solid-phase synthesis using
a PS4 Tribute peptide synthesiser (Protein Technologies, Tucson, AZ, USA). Deprotection of the
Fmoc groups from the amino acids was performed in 20% piperidine in dimethylformamide (DMF).
The coupling of peptide bonds was performed in 11% N-methylmorpholine (NMM) in DMF. After all
the synthesis cycles were finished, the peptide was cleaved from the Rink amide MBHA resin using
94% TFA, 2% 1,2-ethanedithiol (EDT), 2% thioanisole (TIS) and 2% water at room temperature for 4 h.
Next, the cleavage mixture was concentrated and the peptide was precipitated by ice-cold diethyl
ether. Afterwards, the precipitated peptide was washed by ice-cold diethyl ether and dissolved in
20 mL of TFA/water (0.05/99.95, v/v) for lyophilisation.
The synthetic phylloseptin-PTa and phylloseptin-PHa were purified by RP-HPLC and lyophilised
prior being analysed in bioassays. The authenticity of the purified synthetic phylloseptin-PTa and
phylloseptin-PHa was verified by a Waters RP-HPLC system with an analytical RP-HPLC column
(Vydac, C18, 300 Å, 5 µm, 100 mm × 4.6 mm, Hichrom, Berkshire, UK) and MALDI-TOF MS on a
linear time-of-flight Voyager DE mass spectrometer (Voyager DE, Perspective Biosystems) in a positive
detection mode using α-cyano-4-hydroxycinnamic acid matrix.
4.5. Secondary Structure Determination of Novel Peptides by Circular Dichroism
CD spectra were obtained at 20 ◦C using a 1 mm high precision quartz cell (Hellma Analytics,
Essex, UK) with a JASCO J-815 CD spectrometer (Jasco, Essex, UK). The measurement range was
from 250 nm to 190 nm at a scanning speed of 200 nm/min. The bandwidth was 1 nm, and the data
pitch was 0.5 nm. Phylloseptin-PTa and phylloseptin-PHa were respectively dissolved in 10 mM
NH4Ac or 10 mM NH4Ac with 50% TFE to reach a final concentration of 100 µM. The experimental
data were processed via DICHROWEB [35–37] and the α-helicity was calculated by K2D analysis
programme [38].
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4.6. Antimicrobial Susceptibility Assays of Novel Peptides
The antimicrobial activities of phylloseptin-PTa and phylloseptin-PHa were evaluated by the
determination of MIC values against a panel of microorganisms—the Gram-positive bacteria S. aureus
(NCTC 10788), E. faecalis (NCTC12697), and MRSA (NCTC 12493); the Gram-negative bacterium E. coli
(NCTC 10418) and the yeast C. albicans (NCYC 1467). The microorganisms were cultured to their log
phase in Muller-Hinton Broth (MHB), reconstituted to 5× 105 CFU/mL, and subsequently treated with
a series dilution of the peptides. After incubation at 37 ◦C overnight, the growth of microorganisms
was detected at a wavelength of 550 nm using a Synergy HT plate reader (EL808, Biolise BioTek,
Winooski, VT, USA). The MICs were determined as the lowest concentration of peptide where no
growth was detectable.
4.7. Anti-Biofilm Activity using S. aureus Biofilm
Determination of the MBEC of phylloseptin-PTa and phylloseptin-PHa was performed using the
manual MBEC P&G assay (Innovotech, Edmonton, AB, Canada). In detail, the log-phase S. aureus
culture was diluted to 107 CFU/mL and introduced to form biofilms on the surface of the designed
pegs for 72 h. The biofilms formed on the pegs were washed twice by PBS and transferred to a
challenge plate containing 200 µL of peptide solutions at a concentration series ranging from 512 mg/L
to 1 mg/L in doubling dilution. Following incubation at 37 ◦C for 18 h, the pegs were rinsed twice
by PBS and placed in a recovery plate containing 200 µL of 0.5% Tween-80 in MHB. The recovery
plate was subsequently sonicated for 15 min and further incubated for 10 h. The absorbance of the
recovery plate at a wavelength of 550 nm was detected using a Synergy HT plate reader (Biolise BioTek
EL808). The MBEC was determined as the lowest concentration of peptide at which no bacterial
growth was detectable.
4.8. Scanning Electron Microscopy Observation of Complete S. aureus Biofilms and S. aureus Biofilms Treated
with Phylloseptin-PTa and Phylloseptin-PHa
The pegs were broken and fixed in 2.5% glutaraldehyde solution at 4 ◦C overnight. The fixed
biofilms on the pegs were then dehydrated with gradient ethanol 50%, 70%, 90%, 100%, and further
air-dried completely. Scanning electron microscopy for the observation of biofilms was performed
with a Quanta FEG 250 (ThermoFisher Scientific, San Francisco, CA, USA) an acceleration voltage of
30 kV under environmental mode (0.9 mbar) with standard SEM copper tape as background.
4.9. Anticancer Activity Assays of Phylloseptin-PTa and Phylloseptin-PHa
The anticancer activities of phylloseptin-PTa and phylloseptin-PHa against human cells were
evaluated by MTT cell viability assays. H157 non-small cell lung cancer cells were cultured in
RPMI 1640 medium (Life Technology, Paisley, UK) supplemented with 10% fetal bovine serum (FBS)
(Sigma-Aldrich, St. Louis, MO, USA) and 1% penicillin-streptomycin (100 Unit/mL, 100 µg/mL)
(Sigma-Aldrich). Cells were cultured in flasks at 37 ◦C under 5% CO2.
The cells were seeded into 96-well plates (5000 cells/well) and cultured for 24 h, after which,
the cells were starved for 6 h. A peptide stock solution was prepared using DMSO to achieve 10−2 M,
and working solutions were diluted from it in medium without FBS. Cells were challenged with
peptide solutions at a series of concentrations ranging from 10−9 M to 10−4 M and incubated for 24 h.
Then each well received 10 µL of MTT solution (5 mg/mL, Thermo Fisher Scientific). Cells were
cultured for a further 4 h, after which the supernatants were removed from wells and 100 µL of DMSO
were added into all wells. After gentle shaking to dissolve the formazan crystals, the absorbance was
detected at a wavelength of 570 nm using a Synergy HT plate reader (Biolise BioTek EL808). The cell
viabilities at different concentrations of peptide solution were calculated as follows:
Viability% = A/A0× 100%
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where A represents the average absorbance of sample groups at the same concentrations. A0 represents
the average absorbance of vehicle controls (1% DMSO in medium).
The IC50 against different cell lines were determined using GraphPad Prism software (Version 6.0;
GraphPad Software Inc., San Diego, CA, USA). Results were presented as mean ± SEM, and data were
statistically analysed using one-way analysis of variance followed by Dunnett’s multiple comparisons
tests with vehicle control group in GraphPad Prism Software (Version 6.0). Groups of data were
considered to be significantly different if the P value was less than 0.05.
4.10. Cytotoxicity Evaluations of Phylloseptin-PTa and Phylloseptin-PHa
The cytotoxicities of phylloseptin-PTa and phylloseptin-PHa were measured on HMEC-1 cells
using MTT cell viability assay, as described above. Specifically, HMEC-1 cells were grown in
MCDB131 medium (Life Technology) with added 10% FBS, 10 ng/mL epidermal growth factor
(EGF) (Life Technology), 10 mM L-Glutamine (Life Technology) and 1% penicillin-streptomycin
(Sigma-Aldrich). Results were presented as mean ± SEM, and values were compared using one-way
analysis of variance followed by Dunnett’s multiple comparisons tests with vehicle group in GraphPad
Prism Software (Version 6.0). Groups of data were considered to be significantly different if the P value
was less than 0.05.
4.11. Haemolysis Evaluations of Phylloseptin-PTa and Phylloseptin-PHa
A 4% (v/v) suspension of erythrocytes was prepared from defibrinated horse blood (TCS Biosciences
Ltd., Buckingham, UK) by washing and centrifugation for several times. Equal volumes (200 µL)
of peptide solutions and erythrocyte suspensions were incubated together at 37 ◦C for 2 h. Lysis of
erythrocytes was detected by the measurement of supernatant absorbance at a wavelength of 550 nm
using a Synergy HT plate reader (Biolise BioTek EL808). The negative controls consisted of equal
volumes of erythrocyte suspension and PBS and positive control consisted of equal volumes of
erythrocyte suspension and 2% Triton X-100 (Sigma-Aldrich) in PBS solution while the vehicle controls
consisted of equal volumes of erythrocyte suspension and 1% DMSO in PBS solution. The equation for
the calculation of the haemolytic rate was shown below:
Haemolysis% = (A−A0)/(A1−A0)× 100%,
where A represents the average absorbance with peptide treatments, A0 represents the average
absorbance in the vehicle control group and A1 represents the average absorbance in the positive
control group. The HC50 value and HC10 value were determined by GraphPad Prism software
(Version 6.0).
5. Conclusions
In conclusion, the naturally selected AMPs, phylloseptin-PTa, identified from the skin secretion of
P. tarsius, and phylloseptin-PHa, identified from the skin secretion of P. hypochondrialis, showed effective
antimicrobial activities on the tested Gram-positive bacteria and the antibiotic-resistant bacteria
MRSA, and displayed strong biofilm eradicative activity while inhibiting the proliferation of
non-small cell lung cancer cells H157. Interestingly, phylloseptin-PTa demonstrated better potency
than phylloseptin-PHa in all the models that were examined. Therefore, phylloseptin-PTa could be
utilised as an antimicrobial lead to provide new ideas for the development of novel antimicrobial
therapeutics and deserves further comprehensive study.
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Abbreviations
CL cardiolipin
EDT 1,2-ethonedithiol
MBEC minimum biofilm eradication concentration
PC phosphatidylcholine
PE phosphatidylethanolamine
PG phosphatidylglycerol
PS phosphatidylserine
RP-HPLC reversed-phase high performance liquid chromatography
TFA trifluoroacetic acid
TFE trifluoroethanol
TIS thioanisole
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